

BLCA - Bladder Urothelial Carcinoma

Subtype	Proliferation	Prognosis	Therapy (Typical / Investigational)	Common Driver Alterations
Luminal-Papillary	Low	Best	Surgery ± intravesical BCG (NMIBC); FGFR3 inhibitors (erdafitinib) in FGFR3-altered advanced cases	FGFR3 mutations/fusions; KDM6A; STAG2; TERT promoter
Luminal-Infiltrated	Moderate	Good	Chemo + anti-PD-1/PD-L1 immunotherapy; BCG in NMIBC	PIK3CA; ERBB2 amplifications; TERT promoter; high PD-L1
Luminal	High	Intermediate	Platinum-based chemo; immunotherapy; FGFR inhibitors if FGFR3 mutated	TP53; RB1; ERCC2; APOBEC mutational signature
Basal-Squamous	High	Poor	Cisplatin-based chemo; immunotherapy (PD-L1); EGFR-targeted agents in trials	TP53; RB1; CDKN2A deletion; NFE2L2/KEAP1; EGFR overexpression
Neuronal	Very High	Worst	Platinum + etoposide (NE-like regimens); emerging immunotherapy approaches	TP53 + RB1 co-loss; neuroendocrine transcription factors (e.g. NEUROD1); MYCL